
Oct 19, 2026
Press releaseESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentationsSignatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera’s ESMO programAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Soc







